Przejdź do zawartości
Merck

Targeting the pregnane X receptor using microbial metabolite mimicry.

EMBO molecular medicine (2020-03-11)
Zdeněk Dvořák, Felix Kopp, Cait M Costello, Jazmin S Kemp, Hao Li, Aneta Vrzalová, Martina Štěpánková, Iveta Bartoňková, Eva Jiskrová, Karolína Poulíková, Barbora Vyhlídalová, Lars U Nordstroem, Chamini V Karunaratne, Harmit S Ranhotra, Kyu Shik Mun, Anjaparavanda P Naren, Iain A Murray, Gary H Perdew, Julius Brtko, Lucia Toporova, Arne Schön, Bret D Wallace, William G Walton, Matthew R Redinbo, Katherine Sun, Amanda Beck, Sandhya Kortagere, Michelle C Neary, Aneesh Chandran, Saraswathi Vishveshwara, Maria M Cavalluzzi, Giovanni Lentini, Julia Yue Cui, Haiwei Gu, John C March, Shirshendu Chatterjee, Adam Matson, Dennis Wright, Kyle L Flannigan, Simon A Hirota, Ryan Balfour Sartor, Sridhar Mani
ABSTRAKT

The human PXR (pregnane X receptor), a master regulator of drug metabolism, has essential roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off-target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows exploiting previously unexplored parts of chemical space. Here, we report functionalized indole derivatives as first-in-class non-cytotoxic PXR agonists as a proof of concept for microbial metabolite mimicry. The lead compound, FKK6 (Felix Kopp Kortagere 6), binds directly to PXR protein in solution, induces PXR-specific target gene expression in cells, human organoids, and mice. FKK6 significantly represses pro-inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The development of FKK6 demonstrates for the first time that microbial metabolite mimicry is a viable strategy for drug discovery and opens the door to underexploited regions of chemical space.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
SR 12813, ≥98%, solid